SOST and plasma cell myeloma: In contrast, MacDonald et al. showed that the expression of sclerostin was not detected in plasma cells from 630 myeloma patients or 54 myeloma cell lines and that the anti-sclerostin antibody failed to reduce tumor burden [94].